Evidence map›Paper›PMID 36869170›Full record

SynthesisClinical pharmacokinetics2023

Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review.

Prakruti S Rao, Nisha Modi, Nam-Tien Tran Nguyen, Dinh Hoa Vu, Yingda L Xie, Monica Gandhi, Roy Gerona, John Metcalfe, Scott K Heysell, Jan-Willem C Alffenaar

Abstract readSystematic Review
In one paragraph

Synthesis in Clinical pharmacokinetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The Effect of ABCB1 Polymorphisms on the Efficacy of Antidepressants.Basic & clinical pharmacology & toxicology · 2025
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Multidrug-resistant tuberculosis.Nature reviews. Disease primers · 2024
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Prakruti S RaoDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
Nisha Modi *Global TB Institute and Department of Medicine, Rutgers, The State University of New Jersey, Newark, NJ, USA.
Nam-Tien Tran Nguyen *National Drug Information and Adverse Drug Reaction Monitoring Centre, Hanoi University of Pharmacy, Hanoi, Vietnam.
Dinh Hoa Vu *National Drug Information and Adverse Drug Reaction Monitoring Centre, Hanoi University of Pharmacy, Hanoi, Vietnam.
Yingda L Xie *Global TB Institute and Department of Medicine, Rutgers, The State University of New Jersey, Newark, NJ, USA.
Monica GandhiDivision of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Roy GeronaMaternal-Fetal Medicine Division, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, CA, USA.
John MetcalfeDivision of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco, CA, USA.
Scott K HeysellDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
Jan-Willem C AlffenaarPharmacy School, The University of Sydney, Pharmacy Building (A15), Science Road, Sydney, NSW, 2006, Australia. johannes.alffenaar@sydney.edu.au.ORCID 0000-0001-6703-0288

Funding

Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and AdultsR01AI137080 · NIAID · UNIVERSITY OF VIRGINIA · PI Scott K Heysell, Leonid Kagan · 2018 to 2026
$6.3M
Randomized Trial to Optimize Virologic Suppression Rates Using a Point-of-Care Urine Monitoring Assay (ROVING-PUMA)R01AI143340 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2018 to 2026
$5.6M
Novel methods of pharmacologic monitoring for multidrug resistant tuberculosis treatment in the setting of HIV infectionR01AI123024 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, METCALFE, JOHN ZAPATA · 2016 to 2020
$3.6M
“Hair Lengthening”: Using Hair Levels to Interpret Long-Acting PrEP Studies.R37AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2023 to 2026
$3.2M
NIAID NIH HHS R01 AI123024NIAID NIH HHS R01 AI137080NIAID NIH HHS R01 AI143340NIAID NIH HHS R37 AI098472NIH HHS R01 AI137080
6 · The paper itself

Abstract

BACKGROUND AND

objectiveQuantifying exposure to drugs for personalized dose adjustment is of critical importance in patients with tuberculosis who may be at risk of treatment failure or toxicity due to individual variability in pharmacokinetics. Traditionally, serum or plasma samples have been used for drug monitoring, which only poses collection and logistical challenges in high-tuberculosis burden/low-resourced areas. Less invasive and lower cost tests using alternative biomatrices other than serum or plasma may improve the feasibility of therapeutic drug monitoring.

methodsA systematic review was conducted to include studies reporting anti-tuberculosis drug concentration measurements in dried blood spots, urine, saliva, and hair. Reports were screened to include study design, population, analytical methods, relevant pharmacokinetic parameters, and risk of bias.

resultsA total of 75 reports encompassing all four biomatrices were included. Dried blood spots reduced the sample volume requirement and cut shipping costs whereas simpler laboratory methods to test the presence of drug in urine can allow point-of-care testing in high-burden settings. Minimal pre-processing requirements with saliva samples may further increase acceptability for laboratory staff. Multi-analyte panels have been tested in hair with the capacity to test a wide range of drugs and some of their metabolites.

conclusionsReported data were mostly from small-scale studies and alternative biomatrices need to be qualified in large and diverse populations for the demonstration of feasibility in operational settings. High-quality interventional studies will improve the uptake of alternative biomatrices in guidelines and accelerate implementation in programmatic tuberculosis treatment.

Indexed as

Drug MonitoringTuberculosisAntitubercular AgentsHumansAntitubercular Agents

Identifiers

PMID36869170
PMCPMC10042915

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.